Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Ferry

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Presse Medicale (Paris, France : 1983)|April 10, 2012
[Presenting a research project on rare diseases to industrial companies]Antoine Ferry
Medecine Sciences : M/S|June 19, 2018
[The RARE 2017 meeting for companies developing products for rare patients]Antoine Ferry
Medecine Sciences : M/S|April 24, 2014
[Conference 1. An economic observatory for orphan drugs: myth or reality?]Christophe Duguet, Antoine Ferry
Medecine Sciences : M/S|June 19, 2018
[Conclusions of the RARE 2017 meeting]Nathalie Triclin-Conseil, Ségolène Aymé, Antoine Ferry
Presse Medicale (Paris, France : 1983)|April 11, 2012
[Medicoeconomic data on rare disease drugs: a move towards more transparency?]Annick Schwebig, Christophe Duguet, Antoine Ferry, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 8, 2014
The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3β-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patientsSylvie Colin, Bernadette Darné, Amin Kadi, et al.
Therapie|December 17, 2022
Drug repurposing: From the discovery of a useful pharmacological effect to making the treatment available to the patientDominique Deplanque, Christine Fetro, Antoine Ferry, et al.
Therapie|December 23, 2022
Dominique Deplanque, Christine Fetro, Antoine Ferry, et al.
Investigative Ophthalmology & Visual Science|February 11, 2012
Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administrationFrank Cloutier, Matthew Lawrence, Robin Goody, et al.
Ophthalmology|May 10, 2014
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN studyClaus Cursiefen, Eric Viaud, Felix Bock, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Presse Medicale (Paris, France : 1983)|April 10, 2012
[Presenting a research project on rare diseases to industrial companies]Antoine Ferry
Medecine Sciences : M/S|June 19, 2018
[The RARE 2017 meeting for companies developing products for rare patients]Antoine Ferry
Medecine Sciences : M/S|April 24, 2014
[Conference 1. An economic observatory for orphan drugs: myth or reality?]Christophe Duguet, Antoine Ferry
Medecine Sciences : M/S|June 19, 2018
[Conclusions of the RARE 2017 meeting]Nathalie Triclin-Conseil, Ségolène Aymé, Antoine Ferry
Presse Medicale (Paris, France : 1983)|April 11, 2012
[Medicoeconomic data on rare disease drugs: a move towards more transparency?]Annick Schwebig, Christophe Duguet, Antoine Ferry, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 8, 2014
The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3β-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patientsSylvie Colin, Bernadette Darné, Amin Kadi, et al.
Therapie|December 17, 2022
Drug repurposing: From the discovery of a useful pharmacological effect to making the treatment available to the patientDominique Deplanque, Christine Fetro, Antoine Ferry, et al.
Therapie|December 23, 2022
Dominique Deplanque, Christine Fetro, Antoine Ferry, et al.
Investigative Ophthalmology & Visual Science|February 11, 2012
Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administrationFrank Cloutier, Matthew Lawrence, Robin Goody, et al.
Ophthalmology|May 10, 2014
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN studyClaus Cursiefen, Eric Viaud, Felix Bock, et al.
Pageof 1